Abbott Laboratories (ABT) has attracted notable attention in the healthcare market with its promising performance and profitability, resulting in both buy and sell activities by various stakeholders. Multiple entities such as the
Aberdeen Group plc, PDS Planning Inc, McKinley Carter Wealth Services Inc, and Eastern Bank have increased their shareholdings. Many investors are eyeing the company's
Q3 earnings, projecting it to be substantial. Analysts have also given a bullish outlook on Abbott's performance, suggesting a
buy rating. Weiss Ratings, in particular, have assigned a 'Buy (B)' rating. Extra attention has been given to the
Medical Devices Arm ahead of the earnings report, while the
Health Canada Approval of Dissolvable Stent symbolizes a positive shift in the company's medical innovations. Notwithstanding, the company shares were bought and sold across various asset management companies. Yet, overall the company has made a strong name in the sector with its consistent income generation in a dividend stock portfolio and notable growth in its
medical devices based on Q2 2025 earnings call.
Abbott Laboratories ABT News Analytics from Sat, 19 Apr 2025 07:00:00 GMT to Sat, 11 Oct 2025 12:35:31 GMT -
Innovation 8
- Rumor -5
